X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.fiercepharma.com/pharma/fda-rejects-clovis-long-shot-bid-approval-rubraca
https://www.fiercepharma.com/pharma/bankruptcy-clovis-sells-remaining-assets-including-rubraca-70m
https://www.fiercepharma.com/pharma/ema-requests-more-data-fda-spots-potential-harm-clovis-limps-through-rubraca-apps-amid
https://www.biospace.com/article/embattled-clovis-oncology-files-for-chapter-11-sells-radioligand-therapeutic-to-novartis/
https://www.reuters.com/business/healthcare-pharmaceuticals/us-drugmaker-clovis-files-chapter-11-bankruptcy-2022-12-12/
https://www.ema.europa.eu/en/documents/overview/rubraca-epar-medicine-overview_en.pdf
https://www.fiercepharma.com/pharma/free-fall-clovis-defaults-loan-and-agrees-pull-another-indication-rubraca
https://www.fiercepharma.com/pharma/fda-tightens-noose-around-clovis-neck-demanding-rubraca-ovarian-cancer-restriction-after
https://www.fiercepharma.com/pharma/rubraca-faces-question-ovarian-cancer-clovis-oncology-trots-out-prostate-cancer-partial-win
https://www.fiercebiotech.com/biotech/clovis-needs-cash-now-stem-looming-financial-challenges
https://www.fiercepharma.com/marketing/amid-death-risk-fears-clovis-pulls-rubraca-third-line-ovarian-cancer-parp-player-plugs
https://medicine.yale.edu/news-article/yale-cancer-center-study-finds-new-drug-combination-shows-clinical-activity-for-patients-with-prostate-cancer/#:~:text=ESMO%20Prostate%20Cancer%20Study%20Results,resistant%20prostate%20cancer%20(mCRPC).
https://www.businesswire.com/news/home/20210319005072/en/Clovis-Oncology%E2%80%99s-Rubraca%C2%AE-rucaparib-Significantly-Improves-Progression-Free-Survival-versus-Chemotherapy-in-Patients-with-Later-line-Ovarian-Cancer-Associated-with-a-BRCA-Mutation
https://www.businesswire.com/news/home/20201221005205/en/Clovis-Oncology%E2%80%99s-Rubraca%C2%AE-rucaparib-Met-the-Primary-Endpoint-of-Significantly-Improving-Progression-Free-Survival-vs.-Chemotherapy-in-the-ARIEL4-Randomized-Phase-3-Treatment-Study-in-Later-line-Ovarian-Cancer-Patients-with-a-BRCA-mutation
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test
https://www.iqwig.de/en/press/press-releases/talazoparib-in-breast-cancer-hint-of-considerable-added-benefit.13263.html
https://www.businesswire.com/news/home/20200826005806/en/FDA-Approves-FoundationOne%C2%AE-Liquid-CDx-Serve-Rubraca%C2%AE
https://www.businesswire.com/news/home/20200817005082/en/Journal-Clinical-Oncology-Publishes-Additional-Data-Clovis
https://ir.clovisoncology.com/investors-and-news/news-releases/press-release-details/2020/Clovis-Oncology-Announces-Completion-of-Target-Enrollment-in-the-ATHENA-Trial-a-Phase-3-Maintenance-Treatment-Study-in-Front-line-Newly-Diagnosed-Advanced-Ovarian-Cancer/default.aspx
https://ir.clovisoncology.com/investors-and-news/news-releases/press-release-details/2020/Clovis-Oncology-Announces-New-Recommendations-for-Rubraca-rucaparib-Tablets-in-Updated-National-Comprehensive-Cancer-Network-NCCN-Guidelines-for-the-Treatment-of-Metastatic-Castration-Resistant-Prostate-Cancer-mCRPC/default.aspx
https://www.reuters.com/article/us-clovis-oncology-fda/clovis-oncologys-rubraca-gets-fda-approval-for-prostate-cancer-idUSKBN22R2ZQ
https://www.globenewswire.com/news-release/2020/04/13/2015055/0/en/ProLynx-announces-Phase-1B-clinical-trial-of-its-DNA-damaging-agent-PLX038-PEG-SN-38-with-the-PARP-inhibitor-Rubraca-rucaparib-at-the-National-Cancer-Institute.html
http://www.pmlive.com/pharma_news/clovis_leapfrogs_parp_rivals,_filing_rubraca_for_prostate_cancer_1322573
https://www.fiercepharma.com/pharma/will-clovis-s-rubraca-sales-shortfall-revive-talk-a-buyout-at-jp-morgan
https://www.fiercepharma.com/pharma/will-clovis-s-rubraca-sales-shortfall-revive-talk-a-buyout-at-jp-morgan
https://www.fiercepharma.com/pharma/will-clovis-s-rubraca-sales-shortfall-revive-talk-a-buyout-at-jp-morgan
https://www.fiercepharma.com/marketing/as-gsk-and-az-merck-show-off-dazzling-parp-data-where-does-leave-clovis-rubraca
https://endpts.com/a-long-suffering-clovis-makes-a-leap-into-radiopharmaceuticals-paying-12m-in-cash-to-beef-up-the-pipeline/
http://www.pharmafile.com/news/525807/nice-reject-clovis-oncologys-ovarian-cancer-drug-rubraca
https://www.fiercepharma.com/marketing/clovis-investors-lose-faith-as-rubraca-struggles-against-big-pharma-s-marketing-giants
https://www.fiercepharma.com/pharma/gsk-s-zejula-posts-positive-results-first-line-ovarian-cancer-maintenance-regardless?utm_source=internal&utm_medium=rss
https://www.fiercepharma.com/pharma/gsk-wins-fda-priority-review-for-zejula-late-stage-ovarian-cancer
https://www.fiercepharma.com/marketing/clovis-throws-towel-solo-rubraca-study-bladder-cancer
https://endpts.com/clovis-shutters-phii-rubraca-study-after-data-monitors-turn-thumbs-down-on-efficacy/
http://www.pharmafile.com/news/520896/clovis-oncologys-rubraca-shows-promise-multiple-pancreatic-tumour-mutations-interim-data
https://www.businesswire.com/news/home/20190402005328/en/Clovis-Oncology-Announces-Interim-Results-Rubraca%C2%AE-rucaparib/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==
https://www.biospace.com/article/releases/sagard-healthcare-royalty-partners-and-newcastle-university-uk-announce-the-monetization-of-royalty-interest-in-cancer-drug-rubraca/?s=79
http://www.pharmatimes.com/news/rubraca_gets_eu_approval_1276217
Market Place
Share 
